Condition
Cardiovascular Risk
Chronic Kidney Disease
Locations
China
Start date
12/10/2026
Identifiers
Trial ID NN9535-8615,
NCT number NCT07900438,
Eudract number Not Available
NCT number NCT07900438,
Eudract number Not Available
Summary
The purpose of this clinical study is to find out what happens to kidney and heart health during treatment with a medicine called semaglutide, which is given as an injection under the skin. The clinical study will also look at whether this medicine is safe for adults who have type 2 diabetes (T2D) and chronic kidney disease (CKD). This study will last for about 60 to 172 weeks.
Trial Overview:
Treatment
DRUG: Semaglutide
Study type
INTERVENTIONAL
Trial duration
Oct 12 2026 - Jan 24 2030
Participants
300
Phase
IIII
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.